Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)

Exclusion Criteria

• •Safety or tolerability issues arising during the course of SNT-II-001 which in the opinion of the investigator preclude further treatment with idebenone
• •Clinically significant abnormalities of haematology or biochemistry
• •Abuse of drugs or alcohol
• •Use of coenzyme Q10 or idebenone within 30 days prior to inclusion
• •Intake of any investigational drug within 30 days prior to inclusion
• •Symptomatic heart failure
• •Previous history of ventricular arrhythmias (other than isolated ventricular extrasystole); ventricular arrhythmias presented at baseline
• •Known individual hypersensitivity to idebenone or to any of the excipients